Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma We ...

Investigators sought to determine whether there were gender disparities in opportunities to present original research at the ASCO Annual Meeting.

Please provide your email address to receive an email when new articles are posted on . Women appeared less likely to ask questions during Q&A sessions at academic conferences than their male ...

Full disclosure: this paper is based on a presentation I gave in 2019 at an academic conference. I often engage in “double-dipping,” which I would describe as recycling or repurposing your own work ...